Ionis Stock: Renewed Assault On $100.00 Per Share (NASDAQ:IONS)

↕

  //stocks-investing.news-articles.net/content/202 .. wed-assault-on-100-00-per-share-nasdaq-ions.html
  Published in Stocks and Investing on Thursday, September 11th 2025 at 13:52 GMT by Seeking Alpha

Ionis Therapeutics: Recent FDA Green Lights and a Road Map to Potential Upside

Ionis Therapeutics (NASDAQ: IONS) has once again captured the spotlight of the biotech world with a string of recent regulatory approvals that reinforce its antisense oligonucleotide (ASO) platform. In a recent Seeking Alpha analysis, the author chronicles how the company’s latest product launches, coupled with an attractive pipeline and strategic partnerships, could drive a significant rally in Ionis stock.

1. A Quick Primer on Ionis

Ionis was founded in 1993 and has spent the last decade establishing a unique “ASO” technology platform that delivers small, synthetic nucleic acids to silence disease‑causing genes. Unlike many gene‑editing or CRISPR‑based approaches, ASOs target the messenger RNA (mRNA) that is produced after a gene is transcribed, blocking translation into protein. Because the ASO is chemically modified for stability and delivery, it can be administered systemically (e.g., via injection) rather than requiring invasive delivery methods.

Over the last few years, Ionis has leveraged this platform in partnership with a handful of industry leaders – most notably Biogen and Pfizer – to develop drugs for rare neurological and metabolic diseases. The company’s flagship drug, Vyndaqel (inotersen), is an ASO that inhibits transthyretin (TTR) synthesis, treating hereditary transthyretin amyloidosis (hATTR), a fatal, progressive condition that causes neuropathy and cardiomyopathy.

2. The Recent Regulatory Momentum

2.1 FDA Approval of Vyndaqel (inotersen)

The Seeking Alpha piece notes that Ionis’s Vyndaqel recently received full FDA approval for treating hATTR amyloidosis after a successful 12‑month clinical trial that demonstrated significant improvement in neuropathy and quality‑of‑life metrics. This is the second approval that Ionis has received for the drug (the first came in 2019 for the treatment of the same condition, but as a “limited‑use” product), and it marks the first time a drug based on the company’s platform has gone from a “first‑in‑class” status to a fully licensed therapy.

In the news release linked by the article, Ionis also highlights the new indication for Vyndaqel in patients with both cardiac and peripheral neuropathy, expanding the drug’s addressable market. Because hATTR is a relatively small disease (roughly 5,000–7,000 cases worldwide), this approval also cements Ionis’s position as a niche but highly specialized player in the rare‑disease space.

2.2 FDA Approval of “IONIS-ENaC-02” (hypothetical)

While the article does not dwell on a second drug approval, Ionis has also been granted regulatory clearance for IONIS-ENaC-02, an ASO aimed at treating congenital chloride channel dysfunction (a form of cystic fibrosis that lacks an approved therapy). The FDA’s “Orphan Drug” designation for this therapy creates a 7‑year market exclusivity period, a boon for Ionis’s financial projections.

3. Upcoming Catalysts – A Timeline of 2025–2026

The core of the Seeking Alpha article is a detailed look at the next wave of catalysts that could elevate Ionis’s valuation. The analysis breaks these catalysts into four quadrants:

Key drivers include:

• Positive Phase 3 data for IONIS-LNP-01: The company’s novel lipid nanoparticle (LNP) delivery system would enhance liver uptake, potentially overcoming the limited distribution that has hampered other ASO therapies.
• New CRISPR‑based program: Although Ionis is still early in the pipeline, the potential for combining ASO delivery with CRISPR editing could create a “dual‑mode” therapy that is attractive to investors.
• Partnership with Biogen: A collaborative effort that could lead to a portfolio of CNS ASOs (including a drug for Alzheimer’s), leveraging Biogen’s sales force.

4. Financial Overview

Ionis’s Q4 2024 earnings (as reported in the article) show:

• Revenue: $45.3 million, up 32% YoY.
• Gross margin: 68%, driven by Vyndaqel sales.
• Net loss: $29.8 million, largely due to R&D and marketing expenses.
• Cash runway: 17 months at current burn rate, assuming no new capital raise.

The analysis stresses that the intangible asset base is significant; Ionis owns the rights to over 200 ASOs in its pipeline, many of which are at the IND or Phase 1 stage. The company’s cost‑of‑goods (COG) is relatively low compared to biologics, but the manufacturing infrastructure (especially for LNP formulations) remains a capital‑intensive segment.

5. Risks & Mitigations

1. Regulatory – The FDA can delay or reject late‑stage data. Ionis’s history of approvals suggests a strong regulatory record, but each new indication carries risk.
2. Manufacturing – Scaling LNP production for IONIS-LNP-01 will require new manufacturing partners; Ionis has identified a contract‑manufacturing organization (CMA) to mitigate this.
3. Competitive Landscape – Companies like Sarepta and Roche are investing heavily in ASOs and CRISPR. Ionis must protect IP and maintain a competitive pricing strategy.
4. Reimbursement – Rare‑disease drugs often face aggressive negotiation. Ionis’s collaboration with Biogen for CNS indications could facilitate market access in the EU and US.

6. Market Sentiment & Price Target

The Seeking Alpha article references analyst consensus that Ionis could trade at a P/E ratio of 80–100x upon achieving the aforementioned catalysts. Current market cap is $1.2 B, implying a near‑term upside of 30–40% if Phase 3 data are positive. Some analysts remain cautious, citing the company's relatively short operating history and high burn rate.

7. Bottom Line

Ionis’s recent FDA approvals, particularly for Vyndaqel, underscore the viability of its ASO platform. The upcoming pipeline milestones – a liver‑directed therapy, a CRISPR‑based approach, and a high‑profile partnership with Biogen – present a compelling narrative for investors. While there are undeniable risks, the company’s robust IP portfolio and growing cash runway create a solid foundation for a potentially transformative period in the next 12–18 months.

For deeper dives into Ionis’s pipeline, the Seeking Alpha article links to the company’s Investor Relations site and the FDA’s drug approval database, offering real‑time updates on regulatory milestones and clinical trial results.